Back to top

PTC Therapeutics (PTCT) Jumps: Stock Rises 7.2%

Read MoreHide Full Article

PTC Therapeutics, Inc. (PTCT - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 16.8% in the past one-month time frame.

The move came after an analyst upgraded the stock and raised its target price citing the company’s data issued from a recent study of its drug, risdiplam.

The company has seen a mixed track record when it comes to estimate revisions of one increase and one decrease over the past few weeks, while the Zacks Consensus Estimate for the current quarter hasn’t been in a trend either. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

PTC Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Investors interested in the Medical - Drugs industry may consider ChemoCentryx, Inc. (CCXI - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is PTCT going up? Or down? Predict to see what others think:Up or Down

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>
 




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


ChemoCentryx, Inc. (CCXI) - free report >>

PTC Therapeutics, Inc. (PTCT) - free report >>

More from Zacks Tale of the Tape

You May Like